Jade Biosciences, Inc. (JBIO)
Jade Biosciences develops antibody medicines for autoimmune diseases, starting with a candidate for the kidney disease IgA nephropathy. It last closed at $15.40 on Nov 17, up 0.42% on the day.
Key Stats
Last 12 monthsNot reported for this period.
From JBIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 13). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on JBIO in the past 90 days. The average target is $41.00, with a high of $41.00 and a low of $41.00, compared with the last close of $15.40.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | Guggenheim | Maintained | Buy | $41 |
| Aug 11 | Wedbush | Target raised | Buy | $45 → $47 |
| Aug 11 | BTIG | Target raised | Buy | $74 → $77 |
| Jun 15 | UBS | Initiated | Buy | $45 |
| Jun 2 | Wedbush | Maintained | Buy | $45 |
Technical Analysis
The stock is 2% above its 20 day and 2% above its 50 day average. It is 18% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 52). The nearest support is the 50 day average at $15.15, and the nearest resistance the swing high (Oct 22) at $15.44.
| RSI (14) | 51.52 | Middle of its range | Neutral |
| MACD | 0.19 | Above its signal line | Bullish |
| Stochastic | 57.5 | Middle of its range | Neutral |
| ADX (14) | 19.5 | No clear trend | |
| Williams %R | -48.8 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 45.8 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | +5.7% | Change over 10 sessions | Bullish |
| ATR (14) | $1.04 | Typical daily range, 6.7% of price |
| RSI (14) | 44.36 | Middle of its range | Neutral |
| MACD | -1.19 | Below its signal line | Bearish |
| Stochastic | 22.1 | Middle of its range | Neutral |
| ADX (14) | 15.8 | No clear trend | |
| Williams %R | -78.9 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | -55.8 | Oversold below −100, overbought above 100 | Neutral |
| Rate of change | −13.9% | Change over 10 sessions | Bearish |
| ATR (14) | $2.54 | Typical daily range, 16.5% of price |
What happened before
See how JBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How JBIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in JBIO in the last 90 days.
JBIO Institutional Ownership
Full report →- ▲97 buying vs 56 selling
- ▲Held by funds +12.9 pts
- ▲Funds holding +7
- ▲Superinvestors: 2 added, 1 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 162 | 155 | +4.5% |
| In funds' top 10 | 5 | 7 | −28.6% |
| Held by funds | 118.3% | 105.4% | +12.9 pts |
| New / increased | 28 / 69 | 51 / 60 | −12.6% |
| Reduced / sold out | 34 / 22 | 26 / 16 | +33.3% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether JBIO is in one of them and how their past JBIO trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered JBIO in an article yet. Here's the latest on the wider market.
About Jade Biosciences
Jade Biosciences is a biopharmaceutical company based in Waltham, Massachusetts, that is developing antibody medicines for people with autoimmune diseases. Its main candidate, JADE101, targets a signaling protein called APRIL and is being developed first for IgA nephropathy, a progressive kidney disease. The company is also developing JADE201, which targets the BAFF receptor on B cells, for several autoimmune disorders. Its products are still in clinical trials and are not yet sold to patients.
- Headquarters
- Waltham, MA



